Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII activity. Antibodies to epitopes in C2 domain, which is involved in FVIII binding to phospholipids, are highly prevalent. Here, we investigated the effect of phosphatidylserine (PS)-containing liposomes, which bind to C2 domain with high affinity and specificity, upon the immunogenicity of rFVIII. Circular dichroism studies showed that PS-containing liposomes interfered with aggregation of rFVIII. Immunogenicity of free- versus liposomal-rFVIII was evaluated in a murine model of hemophilia A. Animals treated with s.c. injections of liposomal-rFVIII had lower total- and inhibitory titers, compared to animals treated with rFVIII alone. Antigen processing by proteolytic enzymes was reduced in the presence of liposomes. Animals treated with s.c. injections of liposomal-rFVIII showed a significant increase in rFVIII plasma concentration compared to animals that received rFVIII alone. Based on these studies, we hypothesize that specific molecular interactions between PS-containing bilayers and rFVIII may provide a basis for designing lipidic complexes that improve the stability, reduce the immunogenicity of rFVIII formulations, and permit administration by s.c. route.
Ramani
Karthik
K
Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst, New York 14260, USA.
Miclea
Razvan D
RD
Purohit
Vivek S
VS
Mager
Donald E
DE
Straubinger
Robert M
RM
Balu-Iyer
Sathy V
SV
D000818:Animals; D001682:Biological Availability; D005169:Factor VIII / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology* / Q000493:pharmacokinetics; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D051379:Mice; D010718:Phosphatidylserines / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology
D008081:Liposomes; D010718:Phosphatidylserines; D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII
Blood. 1989 Oct;74(5):1618-26
2477082
Blood Rev. 1989 Sep;3(3):180-91
2506958
J Biol Chem. 2005 May 6;280(18):17593-600
15728582
J Immunol. 2005 Feb 1;174(3):1393-404
15661897
J Biol Chem. 1959 Mar;234(3):466-8
13641241
Thromb Haemost. 1999 Feb;81(2):240-4
10063999
Blood. 1998 Nov 15;92(10):3701-9
9808564
Immunopharmacology. 1989 Nov-Dec;18(3):167-76
2532629
J Biol Chem. 1990 Jan 15;265(2):815-22
2104832
Blood. 1990 May 15;75(10):1999-2004
2110840
J Biol Chem. 1992 Aug 5;267(22):15861-8
1639816
J Pharm Sci. 2005 Jun;94(6):1288-99
15858858
J Pharm Sci. 2006 Feb;95(2):358-71
16372314
Nature. 1999 Nov 25;402(6760):439-42
10586887
Pharm Res. 2000 Mar;17(3):344-50
10801224
Immunology. 2000 May;100(1):13-20
10809954
Drugs. 2000 Sep;60(3):547-54
11030466
Biochemistry. 2001 Jan 16;40(2):586-95
11148054
Thromb Haemost. 2000 Nov;84(5):826-32
11127864
Thromb Haemost. 2001 Jan;85(1):125-33
11204564
Blood. 2002 Feb 15;99(4):1215-23
11830468
Semin Thromb Hemost. 2002 Jun;28(3):309-22
12098093
Nat Rev Drug Discov. 2002 Jun;1(6):457-62
12119747
Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719
12501870
Vox Sang. 2002 Aug;83 Suppl 1:403-8
12617176
Semin Thromb Hemost. 2003 Feb;29(1):61-8
12640567
J Thromb Haemost. 2003 Feb;1(2):220-6
12871492
Biol Chem. 2003 Jun;384(6):883-90
12887055
J Thromb Haemost. 2003 Aug;1(8):1777-84
12911593
Biochim Biophys Acta. 2003 Oct 31;1617(1-2):31-8
14637017
Blood Coagul Fibrinolysis. 2004 Mar;15(2):109-24
15090997
J Pharm Sci. 2004 Sep;93(9):2184-204
15295780
J Pharm Sci. 2004 Oct;93(10):2549-57
15349964
Thromb Haemost. 2004 Sep;92(3):522-8
15351848
J Pharm Sci. 2004 Nov;93(11):2645-68
15389672
Biochim Biophys Acta. 1981 Jan 8;640(1):66-81
6163457
Scand J Haematol Suppl. 1984;41:13-24
6440279
Crit Rev Ther Drug Carrier Syst. 1987;3(2):123-93
3542245
Q J Med. 1987 Jun;63(242):473-91
2889239
Immunopharmacology. 1992 May-Jun;23(3):205-13
1500286
Thromb Res. 1992 Jul 1;67(1):57-71
1440515
Pharm Res. 1993 May;10(5):649-59
7686672
Biochim Biophys Acta. 1993 Jul 25;1150(1):9-16
8334142
Biochemistry. 1993 Sep 21;32(37):9577-85
8373765
FEBS Lett. 1993 Jun 21;324(3):325-30
8405375
Thromb Haemost. 1993 Jul 1;70(1):63-7
8236116
Thromb Haemost. 1995 Feb;73(2):247-51
7792738
Nat Genet. 1995 May;10(1):119-21
7647782
Blood. 1995 Sep 1;86(5):1811-9
7544643
Thromb Haemost. 1997 Jul;78(1):647-51
9198232
J Biol Chem. 1997 Jul 18;272(29):18007-14
9218428
Biochim Biophys Acta. 1997 Sep 4;1328(2):261-72
9315622
Pharm Res. 1997 Oct;14(10):1472-8
9358564
J Pharm Sci. 1998 Sep;87(9):1069-76
9724556